Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17523793 | 1.00 | FFAR4 (0.42) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL10268276 | 0.95 | ACACB (0.48) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL8897199 | 0.93 | ACACB (0.52) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL30483471 | 0.93 | ACACB (0.52) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL17523843 | 0.93 | FFAR4 (0.50) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL17523845 | 0.93 | FFAR4 (0.50) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL7404026 | 0.93 | FFAR4 (0.41) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL8895497 | 0.91 | FFAR1 (0.53) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL17523920 | 0.91 | FFAR1 (0.53) | FFAR4ACACBACACAFFAR1NFKB1 | |
| SCHEMBL29229895 | 0.91 | FFAR1 (0.53) | FFAR4ACACBACACAFFAR1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | FFAR4 2413/4885ACACB 1771/4885ACACA 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.